| ID | Age | Sex | State | Date ▼ | Onset Days | Vaccine | Manufacturer | Lot # | Symptoms | Narrative | 💀 | 🏥 | 🚑 | ♿ | ⚠️ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2855781 | 39 | UT | 08/27/2025 |
MMRV VARCEL |
MERCK & CO. INC. MERCK & CO. INC. |
Z007212 |
Extra dose administered, Product administered to patient of inappropriate age, W...
Extra dose administered, Product administered to patient of inappropriate age, Wrong product administered; Extra dose administered, Product administered to patient of inappropriate age, Wrong product administered
More
|
No additional AE; HCP calling to report an AE regarding the PROQUAD vaccine. HCP reported that a 39 ...
No additional AE; HCP calling to report an AE regarding the PROQUAD vaccine. HCP reported that a 39 year old patient inadvertently received the PROQUAD and VARIVAX vaccines concomitantly. HCP reported that the patient was supposed to receive the MMR II and VARIVAX vac; Information has been received from Business Partner/CRO on 19-Aug-2025. This spontaneous report was received from a/an Nurse and refers to a(n) 39-year-old patient of unknown gender. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 19-Aug-2025, the patient started therapy with Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD), (lot #Z007212, expiration date: 05-Oct-2026), dose number 1,. On 19-Aug-2025, the patient started therapy with Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX UPGRADE),, dose number 1, (lot # and expiration date were not reported). On 19-Aug-2025, the patient started therapy with sterile diluent (MERCK STERILE DILUENT), (indication, expiration date, and lot # were not reported). The patient started therapy with Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD), for the treatment of prophylaxis. The patient started therapy with Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX UPGRADE), for the treatment of prophylaxis. On 19-Aug-2025, the patient experienced HCP calling to report an AE regarding the PROQUAD vaccine. HCP reported that a 39 year old patient inadvertently received the PROQUAD and VARIVAX vaccines concomitantly. HCP reported that the patient was supposed to receive the MMR II and VARIVAX vac. On an unknown date, the patient experienced No additional AE. At the reporting time, the outcome of HCP calling to report an AE regarding the PROQUAD vaccine. HCP reported that a 39 year old patient inadvertently received the PROQUAD and VARIVAX vaccines concomitantly. HCP reported that the patient was supposed to receive the MMR II and VARIVAX vac and No additional AE was unknown. The action taken with Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live. nVaricella Virus Vaccine Live (Oka-Merck) and sterile diluent was reported as not applicable.
More
|
|||||||
| 2855782 | 13 | PA | 08/27/2025 |
HPV9 |
MERCK & CO. INC. |
Y020588 |
No adverse event, Product administered at inappropriate site
No adverse event, Product administered at inappropriate site
|
No additional AE; HCP stated that the vaccine was administered "more in the center of the arm.&...
No additional AE; HCP stated that the vaccine was administered "more in the center of the arm." HCP stated that the GARDASIL 9 vaccine was not administered in the deltoid area.; This spontaneous report was received from a medical assistant and refers to a 13-year-old patient of unknown gender. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 18-Aug-2025, the patient was vaccinated with the first dose (in a two dose series) of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) (lot #Y020588, expiration date reported as 11-Aug-2027 and upon internal validation confirmed to be 11-Aug-2027) (route of administration was not reported) 0,5 mL administered a little below the deltoid area, about halfway down the arm between shoulder and elbow, more in the center of the arm for prophylaxis (product administered at inappropriate site). The vaccine was not administered in the deltoid area. No symptoms were reported. No additional adverse event (AE) and no product quality complaint (PQC) was reported (no adverse event).
More
|
|||||||
| 2855783 | OK | 08/27/2025 |
HEPA |
MERCK & CO. INC. |
R006471 |
Expired product administered, No adverse event
Expired product administered, No adverse event
|
No clinical side effects were reported; an expired dose of VAQTA was administered; This spontaneous ...
No clinical side effects were reported; an expired dose of VAQTA was administered; This spontaneous report was received from a nurse and refers to a patient of unknown age and gender. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 12-Jun-2019, the patient was vaccinated with Hepatitis A Vaccine, Inactivated (VAQTA) (lot #R006471, expiration date: 02-Apr-2019) (expired product used) for prophylaxis. No clinical side effects were reported (no adverse event).
More
|
||||||||
| 2855784 | M | FL | 08/27/2025 |
RSV RSV RSV RSV RSV RSV RSV RSV RSV RSV |
GLAXOSMITHKLINE BIOLOGICALS GLAXOSMITHKLINE BIOLOGICALS GLAXOSMITHKLINE BIOLOGICALS GLAXOSMITHKLINE BIOLOGICALS GLAXOSMITHKLINE BIOLOGICALS GLAXOSMITHKLINE BIOLOGICALS GLAXOSMITHKLINE BIOLOGICALS GLAXOSMITHKLINE BIOLOGICALS GLAXOSMITHKLINE BIOLOGICALS GLAXOSMITHKLINE BIOLOGICALS |
UNK UNK UNK UNK UNK UNK UNK UNK UNK UNK |
ADAMTS13 activity decreased, Activated partial thromboplastin time normal, Acute...
ADAMTS13 activity decreased, Activated partial thromboplastin time normal, Acute respiratory failure, Alanine aminotransferase normal, Aspartate aminotransferase increased; Asterixis, Back pain, Bilirubin conjugated increased, Blood bilirubin increased, Blood creatinine increased; Blood electrolytes normal, Blood fibrinogen normal, Blood lactate dehydrogenase increased, Chest X-ray abnormal, Complement factor C3; Complement factor C4, Complement factor normal, Coombs test negative, Crepitations, Eastern Cooperative Oncology Group performance status; Ecchymosis, Echocardiogram, Echocardiogram normal, Ejection fraction normal, Fibrin D dimer increased; Genetic testing, Haemodialysis, Haemoglobin decreased, Haptoglobin decreased, Immature platelet fraction increased; Jugular vein distension, Karnofsky scale, Mental status changes, Metabolic encephalopathy, Metabolic function test normal; Microangiopathic haemolytic anaemia, Multiple organ dysfunction syndrome, Oedema peripheral, Plasmapheresis, Platelet count decreased; Platelet factor 4 decreased, Prothrombin time normal, Pulmonary oedema, Red blood cell burr cells present, Red blood cell schistocytes present; Renal failure, Soluble fibrin monomer complex increased, Thrombotic microangiopathy, Urinary retention, White blood cell count normal
More
|
respiratory syncytial virus vaccine induced thrombotic microangiopathy/vaccine-induced thrombotic mi...
respiratory syncytial virus vaccine induced thrombotic microangiopathy/vaccine-induced thrombotic microangiopathy/microangiopathic hemolytic anemia; metabolic encephalopathy; anuric renal failure; multi-organ failure; acute hypoxic respiratory failure; This serious case was reported in a literature article and described the occurrence of thrombotic microangiopathy in a 91-year-old male patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis. Concurrent medical conditions included low back pain, coronary artery disease (status post bypass grafting), coronary artery bypass graft, aortic valve replacement, sick sinus syndrome (status post pacemaker placement), cardiac pacemaker insertion, hypertension, paroxysmal atrial fibrillation, cardiac failure (with preserved ejection fraction), thoracic aortic aneurysm, chronic anemia, prostate cancer stage iv (status post retro pelvic prostatectomy), prostatectomy, radiation therapy, bone metastases (extensive), crackles lung, jugular vein distension, pedal edema, asterixis, ecchymosis (in the left upper extremity), pulmonary edema and urinary retention. Additional patient notes included Patient had not recently started any other new medications or herbal supplements. Concomitant products included abiraterone acetate, prednisone, leuprorelin acetate (Leuprolide Acetate), ELASOMERAN (MODERNA COVID-19 VACCINE), INFLUENZA VACCINE and rituximab. On an unknown date, the patient received Arexvy. On an unknown date, less than a day after receiving Arexvy, the patient experienced thrombotic microangiopathy (Verbatim: respiratory syncytial virus vaccine induced thrombotic microangiopathy/vaccine-induced thrombotic microangiopathy/microangiopathic hemolytic anemia) (serious criteria hospitalization, GSK medically significant and clinically significant/intervention required), metabolic encephalopathy (Verbatim: metabolic encephalopathy) (serious criteria hospitalization, GSK medically significant and clinically significant/intervention required), anuric renal failure (Verbatim: anuric renal failure) (serious criteria hospitalization, GSK medically significant and clinically significant/intervention required), multi-organ failure (Verbatim: multi-organ failure) (serious criteria hospitalization, GSK medically significant and clinically significant/intervention required) and acute hypoxic respiratory failure (Verbatim: acute hypoxic respiratory failure) (serious criteria hospitalization, GSK medically significant and clinically significant/intervention required). The patient was treated with prednisone. The outcome of the thrombotic microangiopathy and anuric renal failure were resolved and the outcome of the metabolic encephalopathy, multi-organ failure and acute hypoxic respiratory failure were resolving. The reporter considered the thrombotic microangiopathy, metabolic encephalopathy, anuric renal failure, multi-organ failure and acute hypoxic respiratory failure to be related to Arexvy. The company considered the thrombotic microangiopathy, metabolic encephalopathy, anuric renal failure, multi-organ failure and acute hypoxic respiratory failure to be related to Arexvy. Additional Information: GSK Receipt Date 21-AUG-2025. Author reported a patient presented to hospital with severe low back pain and urinary retention. Patient received the new adjuvant RSV vaccine, known as Arexvy, the day prior at a local pharmacy. His past medical history included coronary artery disease status post bypass grafting, bovine aortic valve replacement, sick sinus syndrome status post pacemaker placement, hypertension, paroxysmal atrial fibrillation, heart failure with preserved ejection fraction, chronic thoracic aortic aneurysm, chronic anemia, and stage IV prostate cancer status post retro pelvic prostatectomy followed by radiation therapy with subsequent recurrence with extensive bony metastases. Pertinent outpatient medications included abiraterone acetate, prednisone (5 mg daily), and leuprolide acetate. Patient had not recently started any other new medications or herbal supplements. Patient had received the coronavirus-19 (COVID-19) Moderna vaccine booster 1 month prior to admission and patient had received the Influenza vaccine 3 weeks prior to admission. Patient had baseline Karnofsky and Eastern Cooperative Oncology Group performance scores of 90 percent and 0, respectively. Patient was found to have metabolic encephalopathy and renal failure. His initial labs showed white blood cell count of 7.7 x 10e9 /L, hemoglobin 12.4 g/dL, and platelet count of 112 x 10e9 /L. His complete metabolic profile was normal, except for a creatinine 1.3 mg/dL, and total bilirubin of 2.2 mg/dL. Baseline labs from seven weeks prior were normal including a hemoglobin of 13 g/dL and a platelet count 201x10e9 /L. His last available total bilirubin three months prior was normal. During his hospitalization, his renal failure (Cr 4.1 mg/dL) and encephalopathy worsened, his hemoglobin and platelets continued to decrease, and his AST increased to 95 U/L with normal ALT at 36 U/L. Due to clinical deterioration with no clear diagnosis. Patient was afebrile with pulse rate 60 bpm, respiratory rate 19/min, blood pressure 191/ 108 mmHg, and acute hypoxic respiratory failure requiring 5 L Oxymask to maintain SpO2 more than 90percent. The physical exam was significant for bibasilar crackles in the lungs, jugular venous distention, trace pedal edema, asterixis, ecchymosis in the left upper extremity, and acute metabolic encephalopathy (Glascow Coma Score 9). Laboratory findings include the following (reference ranges listed parenthetically): hemoglobin, 9 g/dL (13.2-16.6 g/ dL); platelet count, 10 x 10e9 /L (135-317x10e9 /L); white blood cell count, 7.1x10e9 /L (3.4-9.6 x 10e9 /L); creatinine, 5.15 mg/ dL (0.75-1.34 mg/dL); total bilirubin, 2.5 mg/dL (less than 1.2 mg/dL); direct bilirubin, 1.0 mg/dL (0-0.3 mg/dL); lactate dehydrogenase, 3080 U/L (122-222 U/L); D-dimer, 33,652 ng/mL (less than 500 ng/mL); haptoglobin, less than 14 mg/dL (30-200 mg/ dL); immature platelet fraction, 15.7percent (1-7percent). Prothrombin time, activated partial thromboplastin time, and fibrinogen were within normal limits. Soluble fibrin monomer was positive. Complement levels on admission included a normal C3 and C4. Chest x-ray revealed bilateral pulmonary edema. Transthoracic echocardiography (TTE) was obtained to assess for the Waring Blender effect, which revealed no prosthetic or periprosthetic regurgitation. The differential diagnosis on admission for this patient with new-onset microangiopathic hemolytic anemia with anuric renal failure and metabolic encephalopathy included TTP, aHUS, disseminated intravascular coagulation (DIC), Waring-Blender syndrome secondary to paravalvular regurgitation, vaccine-induced thrombotic microangiopathy (TMA), or other causes of TMA. Non-TMA etiologies to explain the thrombocytopenia included vaccine-induced immune thrombotic thrombocytopenia (VITT) and heparin-induced thrombocytopenia (HIT). Heparin platelet factor 4 (PF4) antibody and Coombs test were negative. Peripheral smear revealed schistocytes (more than 10/hpf) and burr cells. ADAMTS13 and aHUS/TMA panels were obtained. Due to concern for TTP with multiorgan failure, plasma exchange (PLEX) and hemodialysis were promptly initiated. Given his stable respiratory status and no severe electrolyte abnormalities, PLEX initiation was prioritized over hemodialysis. After the initial PLEX session, the patient demonstrated significant improvement in mental status. Intermittent hemodialysis and prednisone (60 mg daily) were started subsequently. Rituximab therapy was held pending the ADAMTS13 result. The patient received eight sessions of PLEX in total with complete recovery of mental status to baseline within 48 hours. Prednisone (60 mg daily) was administered daily with PLEX until platelets reached 150x10e9 /L for 3 days, after which steroids were tapered over the next few weeks. ADAMTS13 activity results sent before PLEX returned at 67percent (normal more than 70percent) essentially ruling out a diagnosis of TTP, so rituximab was not administered. AHUS/TMA/complement panel returned with the following lab values: total complement 60 (normal 30-75 U/mL), C3 84 (normal 75-175 mg/dL) C4 28 (normal 14-40 mg/dL), factor B complement antigen 36 (normal 30-75 mg/dL), factor H complement antigen 24.7 (normal 18.5-40.8 mg/dL), alternate complement pathway function more than 110percent (normal more than 46percent), SC5b-9 complement 597 (normal less than 251 ng/dL). CBb complement more than 6 (normal less than 1.7 mcg/dL), and C4d complement 2.7 (normal less than 9.9 mcg/dL). Since this panel was not consistent with active alternative complement pathway activation and given the clinical improvement with PLEX, the patient was not started on eculizumab. On the day of discharge (day 11), platelet count was normal at 267x10e9 /L. By discharge, his renal function had not improved, and patient still required hemodialysis. After discharge, his atypical HUS gene panel results showed a double heterozygote status for CFHR1 exon 2-6 deletion, and CFHR3 exon 1-6 deletion. These specific mutations were not well-characterized and were of unclear clinical significance. After discharge, his clinical status continued to improve. Patient completed his course of prednisone, and his renal function improved to the point that patient came off hemodialysis. His most recent labs at 9 weeks post-discharge showed LDH within normal limits at 188 U/L, Hb of 11.4 g/dL, and platelets of 289x10e9 /L. ALT and AST within normal limits at 27 U/L and 33 U/L, respectively. Total bilirubin within normal limits at 0.5 mg/dL with no indirect hyperbilirubinemia. Creatinine normalized at 0.65 mg/dL. Author presented the case of a patient with microangiopathic hemolytic anemia, anuric renal failure and metabolic encephalopathy within 24 hours of administration of the new Arexvy RSV vaccine. Arexvy RSV vaccine data sheets do not report thrombocytopenia or microangiopathic hemolytic anemias to be known adverse events. The patient was heterozygous for a large deletion involving the CFHR1 and CFHR3 genes, strongly suggesting the presence of a contiguous deletion of the full CFHR1 and CFHR3 genes. Specifically, it was noted that the complement factor H (CFH)-CFHR gene cluster was prone to structural variation resulting in large deletions, duplications, and hybrids of genes within the cluster. Currently, the clinical significance of heterozygous copy number variation impacting the CFHR1 and CFHR3 genes was not well-characterized, and the clinical significance of deletions and duplications impacting other genes within the CFHR cluster was not well-delineated. The patient's complement levels were within normal range, except for elevations in CBb and SC5b-9. These complement-level abnormalities indicate activation of the alternative complement pathway, and in the absence of other complement abnormalities this was most likely secondary to post-blood draw activation. Of note, the expected a-HUS lab findings (low factor H, normal C4 and low AH50) were not present. However, prior studies have reported that complement levels may remain normal in aHUS.4 Classically, aHUS was not effectively treated with PLEX, although it was a first-line treatment for Factor H deficiency. RSV vaccine-induced thrombotic microangiopathy with associated multi-organ failure was a diagnosis of exclusion. High dose corticosteroids with PLEX resolved the patient's microangiopathic hemolytic anemia and thrombocytopenia and, in conjunction with intermittent hemodialysis, resolved the patient's acute renal failure.; Sender's Comments: A case of Thrombotic microangiopathy, Metabolic encephalopathy, Renal failure, Multiple organ dysfunction syndrome and Acute respiratory failure, less than a day after receiving Arexvy, in a 91-year-old male patient. Report is consistent with causal relation to the vaccine product, considering plausible time to onset and etiology (RSV vaccine-induced thrombotic microangiopathy with associated multi-organ failure was a diagnosis of exclusion) based on medical history.
More
|
✓ | ||||||
| 2855785 | 08/27/2025 |
VARZOS |
UNKNOWN MANUFACTURER |
UNK |
Chest pain
Chest pain
|
Pain; This non-serious case was reported by a consumer via interactive digital media and described t...
Pain; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of chest pain in a patient who received Herpes zoster (Herpes Zoster vaccine) for prophylaxis. On an unknown date, the patient received Herpes Zoster vaccine. On an unknown date, an unknown time after receiving Herpes Zoster vaccine, the patient experienced chest pain (Verbatim: Pain). The outcome of the chest pain was not reported. It was unknown if the reporter considered the chest pain to be related to Herpes Zoster vaccine. It was unknown if the company considered the chest pain to be related to Herpes Zoster vaccine. Additional Information: GSK receipt date 16-AUG-2025: The patient had the right side of chest feels (illegible) a horse to me (illegible) times and asked what can be taken to ease the pain.
More
|
|||||||||
| 2855786 | F | 08/27/2025 |
MENB |
PFIZER\WYETH |
|
Malaise
Malaise
|
kept getting sick; This is a spontaneous report received from a Pharmacist from medical information ...
kept getting sick; This is a spontaneous report received from a Pharmacist from medical information team. A 19-year-old female patient received meningococcal group b Rlp2086 (TRUMENBA), in Mar2024 as dose 1, single (Batch/Lot number: unknown) for immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: ILLNESS (non-serious), outcome "unknown", described as "kept getting sick". The information on the batch/lot number for meningococcal group b Rlp2086 will be requested and submitted if and when received. Additional information: The reporter called on behalf of the patient with dosing question. The reporter stated that the patient received first dose in Mar2024, never got a second dose kept getting sick, do they need to restart series, or can they administer the second dose.
More
|
||||||||
| 2855787 | 18 | F | 08/27/2025 |
MENB |
PFIZER\WYETH |
|
Incomplete course of vaccination, Influenza, Nasopharyngitis
Incomplete course of vaccination, Influenza, Nasopharyngitis
|
got sick with the flu; sick with a cold; This is a spontaneous report received from a Nurse from med...
got sick with the flu; sick with a cold; This is a spontaneous report received from a Nurse from medical information team. An 18-year-old female patient received meningococcal group b Rlp2086 (TRUMENBA), in Mar2024 as dose 1, single (Batch/Lot number: unknown) at the age of 18 years for immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: NASOPHARYNGITIS (non-serious) with onset Sep2024, outcome "unknown", described as "sick with a cold"; INFLUENZA (non-serious), outcome "unknown", described as "got sick with the flu". Additional information: The consumer was calling on behalf of her daughter. The patient was 19 years at reporting time and last a year in Mar2024 she was 18, and she received a dose one of Trumenba, and she was supposed to return for the second dose on 02Sep2024, 6 months later but in the fall late September she was sick with a cold and they decided to give it a few weeks let her body build up a little bit more immunity, and then she got sick with the flu, and they had to wait again, and one thing led to another and here they were. It had been over a year since the first dose, and they were wondering what should do and if need to go back to the pharmacy for the 2nd dose and that was it or do they need to restart the sequence again, asking what would be the most effective way to go about this, asking if need to take the second dose or restart the whole schedule. No follow-up attempts are possible. Batch/lot number is not provided, and it cannot be obtained.
More
|
|||||||
| 2855788 | 72 | F | FL | 08/27/2025 |
FLU3 FLU3 |
SANOFI PASTEUR SANOFI PASTEUR |
U8764BB U8764BB |
Asthenia, Cough, Influenza like illness, Loss of personal independence in daily ...
Asthenia, Cough, Influenza like illness, Loss of personal independence in daily activities, Myalgia; Oropharyngeal pain, Pyrexia
More
|
Flu-like symptoms; had a fever sore muscle; had a fever sore muscle; still have a bad cough; felt ve...
Flu-like symptoms; had a fever sore muscle; had a fever sore muscle; still have a bad cough; felt very weak and they could not function; sore throat; Initial information received on 22-Aug-2025 regarding an unsolicited valid non-serious case received from a consumer/non-hcp (non-healthcare professional). This case involves a 72 years old female patient who had Flu-like symptoms, sore throat, felt very weak and they could not function, had a fever sore muscle, had a fever sore muscle and still have a bad cough after receiving Influenza Usp Trival A-B High Dose Subvirion Vaccine [Fluzone High Dose]. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On 08-Aug-2025, the patient received an unknown dose of suspect Influenza Usp Trival A-B High Dose Subvirion Vaccine, Suspension for injection in pre-filled syringe (lot U8764BB, expiry date 30-Jun-2026, strength not reported) via unknown route in unknown administration site for Influenza. On 19-Aug-2025, the patient developed sore throat (oropharyngeal pain) (latency 11 days) following the administration of Influenza Usp Trival A-B High Dose Subvirion Vaccine. On 20-Aug-2025, the patient developed felt very weak and they could not function (asthenia) (latency 12 days) following the administration of Influenza Usp Trival A-B High Dose Subvirion Vaccine. On an unknown date, the patient developed had a fever sore muscle (pyrexia), had a fever sore muscle (myalgia) and still have a bad cough (cough) and Flu-like symptoms (latency unknown) following the administration of Influenza Usp Trival A-B High Dose Subvirion Vaccine. Action taken was not applicable. It was not reported if the patient received a corrective treatment for all the events. At time of reporting, the outcome was Unknown for the event (Oropharyngeal pain), (Asthenia), (Myalgia), (Flu-like symptoms) was Not Recovered / Not Resolved for the event (cough) and was Recovered / Resolved on an unknown date for the event (Pyrexia).
More
|
||||||
| 2855789 | 11 | F | AR | 08/27/2025 |
TDAP UNK |
SANOFI PASTEUR UNKNOWN MANUFACTURER |
3CA22C1 U8573AA |
Hyperhidrosis, Loss of consciousness, Retching, Vomiting; Hyperhidrosis, Loss of...
Hyperhidrosis, Loss of consciousness, Retching, Vomiting; Hyperhidrosis, Loss of consciousness, Retching, Vomiting
More
|
Before administering vaccine, patient dad informed me that she fainted 2 years ago after receiving a...
Before administering vaccine, patient dad informed me that she fainted 2 years ago after receiving a flu shot administered by the school nurse. Nurse noted patient appeared anxious and attempted to calm her fears by explaining the procedure before administering vaccine. Patient was sitting next to dad and then moved to chair designated by nurse for immunizations; her father was sitting in front of her and held her hand during series of injections. She received two injections today, (TDAP and MCV). Both injections were tolerated well. After receiving vaccines, patient moved to sit next to her dad, she still appeared anxious but was talking and responding well to her dad. As I got up from the computer to retrieve the printed official copies of immunization records from the copier, I noticed patient suddenly lean forward and then passed out. Her fall was broken by the immunization chair she had just got out of, as she slumped toward the floor. Nurse and Dad grabbed her under each arm and placed her back in the chair, she immediately opened her eyes and made a retching noise. Dad states, "she's going to vomit." Nurse retrieved trash can and patient vomited into trash can. Nurse noted patient was diaphoretic and grabbed some paper towels, wet them with cold water and placed one on patient forehead and one at the base of neck. Nurse placed fan in front of patient to allow cool air to blow on her and assist with calming her down. She was allowed to sit with nurse for assessment, she then verbalized that she felt much better. She required no assistance upon leaving and office with her dad. No s/s of distress noted or voiced.
More
|
||||||
| 2855790 | 45 | M | VA | 08/27/2025 |
COVID19 COVID19 |
PFIZER\BIONTECH PFIZER\BIONTECH |
|
Autonomic nervous system imbalance, Electromyogram, Laboratory test, Nerve condu...
Autonomic nervous system imbalance, Electromyogram, Laboratory test, Nerve conduction studies, Postural orthostatic tachycardia syndrome; Syncope
More
|
Severe Dysautonomia, Postural Orthostatic Tachycardia, Neurally Mediated Syncope
Severe Dysautonomia, Postural Orthostatic Tachycardia, Neurally Mediated Syncope
|
✓ | |||||
| 2855791 | 12 | M | 08/27/2025 |
HPV9 |
MERCK & CO. INC. |
Y018297 |
Syncope
Syncope
|
Vasovagal syncope following vaccine
Vasovagal syncope following vaccine
|
|||||||
| 2855792 | 86 | M | MO | 08/27/2025 |
VARZOS VARZOS |
GLAXOSMITHKLINE BIOLOGICALS GLAXOSMITHKLINE BIOLOGICALS |
23AH3 23AH3 |
Erythema, Injected limb mobility decreased, Laboratory test, Peripheral swelling...
Erythema, Injected limb mobility decreased, Laboratory test, Peripheral swelling, Product administered at inappropriate site; X-ray
More
|
Pt was seen in the ER on 8/22/25 for swelling and redness of Left arm with limited mobility of that ...
Pt was seen in the ER on 8/22/25 for swelling and redness of Left arm with limited mobility of that arm. ER reported that this was due to injection given improperly, states that it appears to be given in the Joint. Lab work and x-ray and referral to Ortho was made. No medications were given and pt followed up with PCP on same day, and no additional medication given or follow up was made at this time.
More
|
||||||
| 2855793 | 57 | F | FL | 08/27/2025 |
FLU3 |
SANOFI PASTEUR |
U8823CA |
Arthralgia, Pain in extremity
Arthralgia, Pain in extremity
|
SHOULDER PAIN DOWN TO ELBOW
SHOULDER PAIN DOWN TO ELBOW
|
||||||
| 2855794 | 45 | F | KS | 08/27/2025 |
TDAP |
GLAXOSMITHKLINE BIOLOGICALS |
9JT4S |
Pain, Pyrexia
Pain, Pyrexia
|
severe body aches, low grade fever, treated with tylenol and ibuprofen, about 24-36 hours
severe body aches, low grade fever, treated with tylenol and ibuprofen, about 24-36 hours
|
||||||
| 2855795 | 38 | F | VA | 08/27/2025 |
HPV9 |
MERCK & CO. INC. |
Z007667 |
Dizziness, Flushing, Hyperhidrosis, Syncope, Vomiting
Dizziness, Flushing, Hyperhidrosis, Syncope, Vomiting
|
Patient received the vaccine and initially tolerated well, after approximately 7 minutes she stated ...
Patient received the vaccine and initially tolerated well, after approximately 7 minutes she stated she felt like she might faint at which time she did experience an episode of vasovagal syncope and collapsed. She was immediately responded to by doctors and nurses, was still feeling flushed, sweating, and dizzy but was oriented to time, place, and situation. She had one episode of vomiting right after this as well. After about 8-10 minutes symptoms began to resolve.
More
|
||||||
| 2855796 | 19 | F | MI | 08/27/2025 |
MENB |
NOVARTIS VACCINES AND DIAGNOSTICS |
9N424 |
Dizziness, Immediate post-injection reaction, Nausea, Pallor
Dizziness, Immediate post-injection reaction, Nausea, Pallor
|
Gave her the Men B shot and immediately after said that she said she felt lightheaded. and felt like...
Gave her the Men B shot and immediately after said that she said she felt lightheaded. and felt like she was going to throw up. had her lye down and gave her a vomit bag just in case. She did not end up throwing up. She did request ice and staff did get her a glass of ice. had provider check on her and when staff got back in the room with her ice she was still lying down and did look pale. She also did want to do her Menveo shot too. Provider talked with her about this and she was ok with getting the menveo. We did offer for her to come back tomorrow to the nurse clinic to get the menveo but patient wanted to get it done today. did give her the menveo while she was lying down and she tolerated well. Had no reaction. Still had her lay down until she felt better. She was fine afterwards and staff ended up walking her to the lobby and asked if she was feeling dizzy while walking and she said she was fine while walking and did not feel dizzy or light headed anymore.
More
|
||||||
| 2855797 | 14 | F | PA | 08/27/2025 |
HPV9 |
MERCK & CO. INC. |
Y015179 |
Mobility decreased, Pain in extremity
Mobility decreased, Pain in extremity
|
8/21/25: C/o arm pain, having trouble raising arm. 8/27/25: continuing arm pain
8/21/25: C/o arm pain, having trouble raising arm. 8/27/25: continuing arm pain
|
||||||
| 2855798 | 1 | M | OR | 08/27/2025 |
HEPA HIBV MMRV PNC20 VARCEL |
MERCK & CO. INC. SANOFI PASTEUR MERCK & CO. INC. PFIZER\WYETH MERCK & CO. INC. |
MF0415 Y007585 Z005152 UK201AC Y010184 |
Extra dose administered, No adverse event; Extra dose administered, No adverse e...
Extra dose administered, No adverse event; Extra dose administered, No adverse event; Extra dose administered, No adverse event; Extra dose administered, No adverse event; Extra dose administered, No adverse event
More
|
Dr patient was given two different types of vaccines by me, first one was MMR & Varicella combo ...
Dr patient was given two different types of vaccines by me, first one was MMR & Varicella combo and one Varicella only vaccine. Provider and supervisor notified as soon as I noticed. Dr informed me what to call and say to parent and supervisor informed me of next steps to take. Dr. informed me to tell parent child received double dose of Varicella and that child will be okay. Parent notified and apricated the nonfiction and will be back in the afternoon to bring her other 2 kids in. If she thought of any questions to ask Dr can address them then as well. No reaction at this time per parent.
More
|
||||||
| 2855799 | 50 | F | GA | 08/27/2025 |
PNC20 PNC20 |
PFIZER\WYETH PFIZER\WYETH |
|
Arthralgia, Dizziness, Erythema, Injection site pain, Injection site swelling; L...
Arthralgia, Dizziness, Erythema, Injection site pain, Injection site swelling; Lymph node pain, Lymphadenopathy, Migraine with aura, Pain, Sleep disorder
More
|
About 8 hours after injection my arm starting feeling sore and hurt to move. I continued to move ar...
About 8 hours after injection my arm starting feeling sore and hurt to move. I continued to move arm as much as possible and also iced it off and on for an hour around 7/8 PM on the night of the injection. I began noticing the more I moved my arm the more it hurt. The pain was a deep intense burning and aching in and around the injection site including my entire shoulder area of my arm as well as into my supraclavicular lymph nodes. At 1:00 after waking up in pain at a 7 out of 10, I took two advil and was able to fall back to sleep. The following day symptoms had subsided to manageable soreness after taking another advil at 7:00am, and then again around 4:00pm. In addition to the pain experienced, my upper arm and lymph node on my left side were swollen. On Wednesday I noticed the swelling had not subsided and now my lymph nodes were red. I worked out this day with some intensity and had to leave feeling light headed. About 2 hours afer leaving the gym I started getting a migraine with auras. As of this time, Wed 27th I have not taken anymore advil and the pain level is around a 5 when raising my arm higher than horizontal.
More
|
||||||
| 2855800 | 0.33 | F | IL | 08/27/2025 |
DTAPHEPBIP DTAPHEPBIP |
GLAXOSMITHKLINE BIOLOGICALS GLAXOSMITHKLINE BIOLOGICALS |
9C295 9C295 |
Ear infection, Injection site erythema, Injection site mass, Irritability, Pyrex...
Ear infection, Injection site erythema, Injection site mass, Irritability, Pyrexia; Teething
More
|
The child has been experiencing a lump on her right leg for approximately 2 weeks. The lump is locat...
The child has been experiencing a lump on her right leg for approximately 2 weeks. The lump is located beneath the skin and has not shown any signs of resolution. The area around the lump exhibits intermittent redness, which is sometimes severe and at other times absent. The lump is situated directly under the site of a previous injection given during her 4-month vaccinations. Despite the presence of the lump, she appears to be unaffected, maintaining her usual mobility. However, she has been more irritable than usual, a change that coincided with ear infections. She is currently on amoxicillin. The lump does not seem to cause discomfort when touched, and there is no evidence of drainage. She has also experienced intermittent fevers, which were initially attributed to teething. Her last recorded fever was 1 day ago, but since starting the antibiotic, her temperature has remained between 98 and 99.8 degrees.
More
|
||||||
| 2855801 | 69 | F | GA | 08/27/2025 |
HEPAB HEPAB HEPAB |
GLAXOSMITHKLINE BIOLOGICALS GLAXOSMITHKLINE BIOLOGICALS GLAXOSMITHKLINE BIOLOGICALS |
|
Arthralgia, Back pain, Chest pain, Cough, Dry eye; Dysstasia, Eye pruritus, Eye ...
Arthralgia, Back pain, Chest pain, Cough, Dry eye; Dysstasia, Eye pruritus, Eye swelling, Facial pain, Gait disturbance; Musculoskeletal chest pain, Musculoskeletal discomfort, Neck pain, Pain in extremity, Wheelchair user
More
|
Pain in my toes, feet, hips, lower back, swollen dry itchy eyes, dry cough. The symptoms got worse ...
Pain in my toes, feet, hips, lower back, swollen dry itchy eyes, dry cough. The symptoms got worse over the next few days to be severe pain in my feet, hands, hips, lower back, dry cough, itchey eyes- the pain was severe and I was unable to walk well and could not stand any pressure on my feet or hands. Starting taking Ibuprofen 400 mg every four hours with very little relief. Staring taking 8mg of Prednisone a day, starting have some refliet right away on day one. On day 6 of Prednisone was able to walk very short distances. On day 6 decresed my prednisone dose to 4 mg a day- pain in feet and hands resovled, but hip are painful to walk or lay on my hips. Continued Prednisone at 4mg a day for the next 20 days. During these 20 days, had pain in my hips, occasional pain in bilateral lower rib cage, dry cough, itchy eyes. On Aug 14 I woke up at 2:30 Am with severe pain in my entire chest, up my neck, and in my face-feared a heart attack-pulse was stable and I sat up and waited a few minutes and the pain subsided. Started having severe pain in both anckles. Aug 26 Had to use a wheelchair to get through the airport, as I could not walk the 1 mile distance to the departure gate. As of today Aug 27 have discomfort in my ankles and hips will take 2mg prednisone for the next two days. See my Doctor on Aug 28th.
More
|
||||||
| 2855802 | 59 | M | SC | 08/27/2025 |
FLU3 PNC21 TDAP VARZOS |
SANOFI PASTEUR MERCK & CO. INC. SANOFI PASTEUR GLAXOSMITHKLINE BIOLOGICALS |
tfaa2504 z003579 u83538a gj952 |
Paraesthesia oral; Paraesthesia oral; Paraesthesia oral; Paraesthesia oral
Paraesthesia oral; Paraesthesia oral; Paraesthesia oral; Paraesthesia oral
|
patient said his tongue felt tingle
patient said his tongue felt tingle
|
||||||
| 2855803 | 57 | M | WY | 08/27/2025 |
COVID19 |
PFIZER\BIONTECH |
|
Condition aggravated, Hyperacusis, Tinnitus
Condition aggravated, Hyperacusis, Tinnitus
|
My tinnitus definitely got worse and my ears more sensitive--an increase in hyperacusis. I'm st...
My tinnitus definitely got worse and my ears more sensitive--an increase in hyperacusis. I'm still feeling it 8 months later.
More
|
||||||
| 2855804 | 38 | F | CA | 08/27/2025 |
TDAP |
GLAXOSMITHKLINE BIOLOGICALS |
DR2GR |
Documented hypersensitivity to administered product, Hypoaesthesia, Malaise
Documented hypersensitivity to administered product, Hypoaesthesia, Malaise
|
Patient was allergic to dtap per documentation patient was feeling body numbness and feeling sick m...
Patient was allergic to dtap per documentation patient was feeling body numbness and feeling sick medical assistant administered TDAP before provider order. Patient not feeling well patient was send to emergency room per provider per provider direction.
More
|
||||||
| 2855805 | 18 | M | 08/27/2025 |
HEP IPV MMRV MNQ VARCEL |
DYNAVAX TECHNOLOGIES CORPORATION SANOFI PASTEUR MERCK & CO. INC. SANOFI PASTEUR MERCK & CO. INC. |
3N2ND Y1A201M Z008499 U8361AA Z004454 |
Extra dose administered, Wrong product administered; Extra dose administered, Wr...
Extra dose administered, Wrong product administered; Extra dose administered, Wrong product administered; Extra dose administered, Wrong product administered; Extra dose administered, Wrong product administered; Extra dose administered, Wrong product administered
More
|
Patient was given MMRV instead of MMR. In addition, he received Varicella, which makes the MMRV redu...
Patient was given MMRV instead of MMR. In addition, he received Varicella, which makes the MMRV reduntant. The vaccines were pulled and prepared by 2 separate nurses for the same patient and before drawing up and administering were not specifically double checked against the recommendations before administered. No adverse patient symptoms occured and the error was noted upon entering the vaccines into records at the end of the visit.
More
|
|||||||
| 2855806 | 75 | F | FL | 08/27/2025 |
RSV |
GLAXOSMITHKLINE BIOLOGICALS |
GE3S7 |
Extra dose administered, No adverse event
Extra dose administered, No adverse event
|
Patient received duplicate vaccine dose when vaccine is supposed to be a one dose series. Patient di...
Patient received duplicate vaccine dose when vaccine is supposed to be a one dose series. Patient did not experience any adverse events.
More
|
||||||
| 2855807 | 77 | M | FL | 08/27/2025 |
RSV |
GLAXOSMITHKLINE BIOLOGICALS |
GE3S7 |
Extra dose administered, No adverse event
Extra dose administered, No adverse event
|
Patient received duplicate vaccine dose when vaccine is supposed to be a one dose series. Patient di...
Patient received duplicate vaccine dose when vaccine is supposed to be a one dose series. Patient did not experience any adverse events.
More
|
||||||
| 2855808 | 19 | F | CA | 08/27/2025 |
MENB |
PFIZER\WYETH |
GX1463 |
No adverse event, Product substitution error
No adverse event, Product substitution error
|
The patient is 19 years old. The vaccine was mistakenly taken from the refrigerator; however, the pa...
The patient is 19 years old. The vaccine was mistakenly taken from the refrigerator; however, the patient was due for this vaccine. The patient had previously received the Trumemba vaccine without any adverse reactions. This report is being submitted to document that a vaccine was administered instead of a vaccine. The patient experienced no adverse reaction following administration.
More
|
||||||
| 2855809 | 23 | F | ID | 08/27/2025 |
UNK |
UNKNOWN MANUFACTURER |
p-y004552 |
Underdose
Underdose
|
she received 19 yr only dose and not 20+
she received 19 yr only dose and not 20+
|
||||||
| 2855810 | 1.25 | F | OR | 08/27/2025 |
HEPA MMRV VARCEL |
GLAXOSMITHKLINE BIOLOGICALS MERCK & CO. INC. MERCK & CO. INC. |
42DMP Y019465 Y005919 |
Extra dose administered, No adverse event; Extra dose administered, No adverse e...
Extra dose administered, No adverse event; Extra dose administered, No adverse event; Extra dose administered, No adverse event
More
|
patient did not have any adverse event, so side effects. It was a vaccine error . Patient received t...
patient did not have any adverse event, so side effects. It was a vaccine error . Patient received that MMRV vaccine and the VAR vaccine. patient received two dose of VAR at one time.
More
|
||||||
| 2855811 | 5 | M | NC | 08/27/2025 |
MMR TDAP VARCEL |
MERCK & CO. INC. GLAXOSMITHKLINE BIOLOGICALS MERCK & CO. INC. |
Y007623 CX4HL Y011018 |
Product administered to patient of inappropriate age, Wrong product administered...
Product administered to patient of inappropriate age, Wrong product administered; Product administered to patient of inappropriate age, Wrong product administered; Product administered to patient of inappropriate age, Wrong product administered
More
|
Pt is a 5 year old, was due for a Dtap but was given a Tdap - this was to be his 4th Dtap
Pt is a 5 year old, was due for a Dtap but was given a Tdap - this was to be his 4th Dtap
|
||||||
| 2855812 | 1.83 | M | AR | 08/27/2025 |
DTPPVHBHPB HEPA IPV MMR |
MSP VACCINE COMPANY GLAXOSMITHKLINE BIOLOGICALS SANOFI PASTEUR MERCK & CO. INC. |
U8265AA J4K4X X1D141M Y014095 |
Extra dose administered, Pyrexia; Extra dose administered, Pyrexia; Extra dose a...
Extra dose administered, Pyrexia; Extra dose administered, Pyrexia; Extra dose administered, Pyrexia; Extra dose administered, Pyrexia
More
|
Administered Vaxelis and IPOV resulting in him receiving extra dose of Polio vaccine. Notified mothe...
Administered Vaxelis and IPOV resulting in him receiving extra dose of Polio vaccine. Notified mother and she stated only side effect he had was fever the night off, but that is usual for him after vaccines
More
|
||||||
| 2855813 | 67 | F | FL | 08/27/2025 |
VARZOS |
GLAXOSMITHKLINE BIOLOGICALS |
|
Cellulitis, Hypersensitivity
Cellulitis, Hypersensitivity
|
cellulitis, allergic reaction
cellulitis, allergic reaction
|
||||||
| 2855814 | 79 | F | CA | 08/27/2025 |
COVID19 PNC20 |
PFIZER\BIONTECH PFIZER\WYETH |
ME6072 LX4486 |
Death, Nausea, Unresponsive to stimuli, Vomiting; Death, Nausea, Unresponsive to...
Death, Nausea, Unresponsive to stimuli, Vomiting; Death, Nausea, Unresponsive to stimuli, Vomiting
More
|
Resident developed nausea and vomiting on 08/23/2025 at 1500, resident vomited x2 Ordered zofran f...
Resident developed nausea and vomiting on 08/23/2025 at 1500, resident vomited x2 Ordered zofran from MD PRN. Resident still monitored every shift with no episodes noted for the ff shift. Resident still eating her meals for dinner and breakfast. Around shower time the next day resident noted to be non responsive while up on the shower chair. Transferred to bed, no vitals obtained. Resident is DNR.
More
|
✓ | |||||
| 2855815 | 4 | M | CA | 08/27/2025 |
VARCEL |
MERCK & CO. INC. |
Y017915 |
Inappropriate schedule of product administration, No adverse event
Inappropriate schedule of product administration, No adverse event
|
Varicella vaccine administered 08/26/25, less than 28 days after prior MMR vaccine. Per CDC guidelin...
Varicella vaccine administered 08/26/25, less than 28 days after prior MMR vaccine. Per CDC guidelines, minimum interval between two live vaccines is 28 days. Varicella dose invalid. No adverse effects noted or reported.
More
|
||||||
| 2855816 | 71 | M | KS | 08/27/2025 |
PNC20 PNC20 |
PFIZER\WYETH PFIZER\WYETH |
21-Valent 21-Valent |
Chills, Dizziness, Fatigue, Injection site erythema, Injection site reaction; Na...
Chills, Dizziness, Fatigue, Injection site erythema, Injection site reaction; Nausea, Pyrexia, Urticaria, Vomiting
More
|
vomiting, dizziness, nausea, fever, chills, fatigue.... went to emergency room by paramedics. 2 da...
vomiting, dizziness, nausea, fever, chills, fatigue.... went to emergency room by paramedics. 2 days later at vaccination site in upper left arm a huge red welt appeared that went down my arm and I went to urgent care; can send a picture
More
|
||||||
| 2855817 | 18 | M | OH | 08/27/2025 |
MNQ MNQ |
SANOFI PASTEUR SANOFI PASTEUR |
U8370AA U8370AA |
Feeling abnormal, Loss of consciousness, Muscle rigidity, Opisthotonus, Skin dis...
Feeling abnormal, Loss of consciousness, Muscle rigidity, Opisthotonus, Skin discolouration; Urinary incontinence
More
|
Client received menACWY vaccine. He began eating a sucker right after the injection. He started to l...
Client received menACWY vaccine. He began eating a sucker right after the injection. He started to lean forward and said, "I don't feel right." This nurse caught him and sat him up in the chair, his body became rigid as he arched his back. Client became incontinent of urine. Client placed on the floor, legs elevated. His mental status returning, cool compress placed on forehead. Respirations easy, non-labored. Client began eating his sucker again. Color rapidly returning to normal. Client states he doesn't remember anything about passing out. Client's mental status returned to normal per mother. Mother was present during the entire event. Client states all symptoms are gone, he feels fine. Client's mother states he looks his normal self. Client discharged from the Health Department in apparent stable condition.
More
|
||||||
| 2855818 | 1 | M | PA | 08/27/2025 |
MMR |
MERCK & CO. INC. |
Y017528 |
Injection site erythema, Injection site urticaria
Injection site erythema, Injection site urticaria
|
About 2 minutes after receiving the vaccine patient developed 3 hives and redness the size of a half...
About 2 minutes after receiving the vaccine patient developed 3 hives and redness the size of a half dollar at the injection site of the MMR vaccine. This was reported to the patients PCP who then ordered PO Benadryl given in office. Instructed to wait another 10 minutes in the office. Patient was evaluated by the PCP who stated his chest was clear and denies facial swelling or and difficulties swallowing. Mother was advised by PCP to give Benadryl every 6 hours for 24 - 48 hours. ED precautions were reviewed with mother.
More
|
||||||
| 2855819 | 5 | F | ME | 08/27/2025 |
DTAPIPV MMRV |
SANOFI PASTEUR MERCK & CO. INC. |
U8009AB Z002987 |
Inappropriate schedule of product administration; Inappropriate schedule of prod...
Inappropriate schedule of product administration; Inappropriate schedule of product administration
More
|
Quadracel was given when the child had never been vaccinated previously. Quadracel is only for the f...
Quadracel was given when the child had never been vaccinated previously. Quadracel is only for the final dose of DTaP and IVP.
More
|
||||||
| 2855820 | 1.58 | F | OH | 08/27/2025 |
DTAP |
GLAXOSMITHKLINE BIOLOGICALS |
BH57H |
Injection site erythema, Injection site swelling, Injection site warmth
Injection site erythema, Injection site swelling, Injection site warmth
|
Right arm became red, swollen and hot to the touch on 8/27/25 around noon per the parent.
Right arm became red, swollen and hot to the touch on 8/27/25 around noon per the parent.
|
||||||
| 2855821 | 6 | M | ME | 08/27/2025 |
DTAPIPV |
SANOFI PASTEUR |
U8009AB |
Inappropriate schedule of product administration
Inappropriate schedule of product administration
|
Quadracel given as third dose of DTaP and IPV. Quadracel is only for the final dose of DTaP and IPV
Quadracel given as third dose of DTaP and IPV. Quadracel is only for the final dose of DTaP and IPV
|
||||||
| 2855822 | 19 | F | 08/27/2025 |
HEP |
GLAXOSMITHKLINE BIOLOGICALS |
AZ453 |
Incorrect dose administered
Incorrect dose administered
|
Patient is 19 years old, nurse accidently gave adult hepatitis B instead of pediatric.
Patient is 19 years old, nurse accidently gave adult hepatitis B instead of pediatric.
|
|||||||
| 2855823 | 16 | M | GA | 08/27/2025 |
MENB MENB |
NOVARTIS VACCINES AND DIAGNOSTICS NOVARTIS VACCINES AND DIAGNOSTICS |
|
Computerised tomogram normal, Headache, Laboratory test normal, Micturition urge...
Computerised tomogram normal, Headache, Laboratory test normal, Micturition urgency, Nausea; Pollakiuria, Urinary incontinence, Urine analysis normal, Vomiting
More
|
My son received both meningitis vaccines on 8/21/25 and started having a headache within the hour. ...
My son received both meningitis vaccines on 8/21/25 and started having a headache within the hour. As the day progressed, he started with urgency and frequency in urination, nausea, vomiting, and then eventually urinary incontinence. We went to urgent care on 8/22/25 and they sent us to the pediatric ER. They did labs, urinalysis, and a CT scan. Ultimately, they decided to keep him overnight for a possible MRI the next day. However, his symptoms started fading away and within 48 hours completely gone. I questioned reporting these symptoms however I can't seem to contribute them to anything else. I spoke with an RN who informed me to report them.
More
|
||||||
| 2855824 | 13 | M | TN | 08/27/2025 |
HEP IPV MMR TDAP VARCEL |
GLAXOSMITHKLINE BIOLOGICALS SANOFI PASTEUR MERCK & CO. INC. SANOFI PASTEUR MERCK & CO. INC. |
3N2ND Y1A201M Y013130 4CA28C1 Z004245 |
Extra dose administered; Extra dose administered; Extra dose administered; Extra...
Extra dose administered; Extra dose administered; Extra dose administered; Extra dose administered; Extra dose administered
More
|
Patient DOB entered incorrectly. Corrected DOB in records and updated. Then assessed immune registr...
Patient DOB entered incorrectly. Corrected DOB in records and updated. Then assessed immune registry and only saw one account. The following vaccines were assessed as needed: Tdap, Hep B, IPV, MMR, and Varicella. Vaccines administered. After administration refreshed immune registry and saw patient was duplicated. Reassessed vaccines. Patient needed Tdap vaccine, but did not need Hep B, IPV, MMR, or Varicella vaccines. Parent notified.
More
|
||||||
| 2855825 | 24 | M | 08/27/2025 |
HEP |
MERCK & CO. INC. |
Y004552 |
Underdose
Underdose
|
Patient given the 19 only, was supposed to get the 20 and up.
Patient given the 19 only, was supposed to get the 20 and up.
|
|||||||
| 2855826 | 4 | F | NY | 08/27/2025 |
DTAPIPV MMRV |
SANOFI PASTEUR MERCK & CO. INC. |
|
Expired product administered, No adverse event; Expired product administered, No...
Expired product administered, No adverse event; Expired product administered, No adverse event
More
|
No Symptoms. Expired vaccine administered.
No Symptoms. Expired vaccine administered.
|
||||||
| 2855827 | 66 | M | OR | 08/27/2025 |
COVID19 |
MODERNA |
203J23A |
Brain fog, Dizziness, Loss of employment, Malaise
Brain fog, Dizziness, Loss of employment, Malaise
|
I got dizzy and then i got brain fog, and i have a list of the symptoms, I am better but some do lin...
I got dizzy and then i got brain fog, and i have a list of the symptoms, I am better but some do linger. I was hoping it would go away and i got to see my new doctor 3 weeks after the vaccine, and it took him by surprise. I went to facility twice. I lost my job over this and i have been sick ever since, I had over 35 symptoms.
More
|
||||||
| 2855828 | 16 | M | PA | 08/27/2025 |
HPV9 |
MERCK & CO. INC. |
Z007667 |
Pain, Pain in extremity, Tenderness
Pain, Pain in extremity, Tenderness
|
Extreme arm soreness for over a week. Arm is fully mobile, however is painful to touch and move. Tri...
Extreme arm soreness for over a week. Arm is fully mobile, however is painful to touch and move. Tried heat, movement, pain medication.
More
|
||||||
| 2855829 | 56 | M | OR | 08/27/2025 |
VARZOS |
GLAXOSMITHKLINE BIOLOGICALS |
99ds2 |
Myalgia, Pain
Myalgia, Pain
|
Pt reported a throbbing muscle pain. Feeling like a muscle cramp that come and go. It lasted several...
Pt reported a throbbing muscle pain. Feeling like a muscle cramp that come and go. It lasted several month after the first dose.
More
|
||||||
| 2855830 | 15 | F | CO | 08/27/2025 |
MNQ |
NOVARTIS VACCINES AND DIAGNOSTICS |
U8508AA |
Inappropriate schedule of product administration
Inappropriate schedule of product administration
|
none, vaccine was given 4 months early
none, vaccine was given 4 months early
|